N. Turner

L. Biganzoli, G. Sanna, N. Turner, 2013, EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.].

Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients

M. Pestrin, M. Pazzagli, A. Di Leo, 2015, Molecular oncology.

Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria

P. Gibbs, M. Christie, J. Desai, 2016, International journal of cancer.

Continued value of adjuvant anthracyclines as treatment for early breast cancer.

A. Di Leo, L. Biganzoli, N. Turner, 2015, The Lancet. Oncology.

Primary Tumor Resection in Patients With Metastatic Colorectal Cancer Is Associated With Reversal of Systemic Inflammation and Improved Survival.

P. Gibbs, J. Desai, J. Tie, 2015, Clinical colorectal cancer.

Targeting triple negative breast cancer: is p53 the answer?

G. Del Sal, M. D’Incalci, L. Santarpia, 2013, Cancer treatment reviews.

RESPONSE OF CML TO MEK INHIBITION 1-1-Cellular mechanisms underlying complete hematological response of chronic myeloid leukemia to BRAF and MEK 1 / 2 inhibition in a patient with concomitant metastatic melanoma

A. Roberts, A. Behren, J. Cebon, 2015 .

Examining the impact of regular aspirin use and PIK3CA mutations on survival in stage 2 colon cancer

P. Gibbs, M. Christie, J. Desai, 2017, Internal medicine journal.

A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme

I. Davis, J. Cebon, M. Andrews, 2014, Melanoma research.

The Changing Face of Noncardia Gastric Cancer Incidence Among US Non-Hispanic Whites

P. Rosenberg, J. Fraumeni, W. Anderson, 2018, Journal of the National Cancer Institute.

The continued evidence from overviews: what is the clinical utility?

M. Pestrin, A. Di Leo, L. Biganzoli, 2013, Breast.

Breast cancer in the elderly: which lessons have we learned?

L. Biganzoli, N. Turner, D. Becheri, 2013, Future oncology.

Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study

C. Hudis, L. Norton, P. Morris, 2015, Molecular oncology.

Risk-adjusted pathologic margin positivity rate: a problematic quality indicator.

P. Gibbs, H. Wong, N. Turner, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multifactorial ‘Consensus Signature’ by in silico analysis to predict response to neoadjuvant anthracycline-based chemotherapy in triple-negative breast cancer

S. Bicciato, M. Forcato, A. Di Leo, 2015, npj Breast Cancer.

Feasibility and safety of dose-dense docetaxel after conventional epirubicin and cyclophosphamide as adjuvant treatment for early breast cancer patients.

A. Leo, M. Pestrin, L. Biganzoli, 2013, Breast.

Novel quality indicators for metastatic colorectal cancer management identify significant variations in these measures across treatment centers in Australia

P. Gibbs, J. Desai, J. Tie, 2015, Asia-Pacific journal of clinical oncology.

Continued value of adjuvant anthracyclines as treatment for early breast cancer.

A. Di Leo, L. Biganzoli, N. Turner, 2015, The Lancet. Oncology.

Adjuvant chemotherapy: which patient? What regimen?

M. Pestrin, A. Di Leo, L. Biganzoli, 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.